Financial releases

First injections of ZENEO® Midazolam for the clinical bioequivalence study

2021 annual results - First Marketing Authorization (MA) applications expected to be filed in 2023

Conformity of the first industrial transposition batch of Zeneo® Hydrocortisone

Crossject strengthens its financial resources and gives all shareholders an interest in the 2022 outlook through a free allocation of equity warrants

Validation of the ZENEO® Midazolam clinical batch

Good Manufacturing Practices certificate issued by the ANSM

First-half 2021 results and business update

US & Canada licensing agreement with Eton Pharmaceuticals for Crossject’s ZENEO® Hydrocortisone

2020 Annual results and business update

Crossject benefits from The French National Recovery Plan, with a €1.5 million grant